According to an American Banking and Market News report, the board of directors of Northrop Grumman Corporation (NOC) announced a quarterly dividend - of $0.70 per share - on Northrop Grumman common stock, on Wednesday.
Falls Church, Virginia-based NOC provides products, services, and integrated solutions in aerospace, electronics, information and services to its clients across the globe.
The $0.70-per-share quarterly dividend announced by NOC represents a $2.80-per-share dividend on an annualized basis, and a yield of 2.18 percent.
The quarterly dividend declared by the NOC board of directors will be payable to the shareholders on September 17, 2014. All shareholders of record as of the close of business on September 2, 2014, will be paid the quarterly dividend.
Meanwhile, in its last-released earnings report released on July 23, the earnings per share (EPS) reported by NOC for the April-June quarter stood at $2.37, which was $0.15 more than the analysts' consensus estimate of $2.22 EPS.
Moreover, NOC's revenue for that quarter was $6.00 billion, which also surpassed the consensus estimated quarterly revenue of $5.97 billion.
In its annual Environmental Responsibility Report for fiscal year 2015 released last Thursday, tech giant Apple has revealed that nearly 90 million pounds of unwanted or broken electronics were processed by the company over the last one year....
A new study by the Massachusetts Institute of Technology (MIT) has revealed that Istanbul lies...
The Michael J Fox Foundation is aiming to test wearable sensors in smart watches made by Intel's...
There was a time just a few years back when Spain ranked second after Greece, as a figure of the euro zone's huge debt crisis and economic slowdown. The country's unemployment climbed to a huge twenty seven percent and the economy was still...
In January, trade surplus of Germany decreased since plunge in imports was more than a drop in...
On Tuesday, tech giant Google released latest to show how much of its online traffic is...
German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.
On Monday, Darmstadt, Germany-based Merck said...
There are a lot of things not going right at the IRS and...
On Thursday, the US Federal Bureau of Investigation (FBI...
In an announcement made via a blog post on Thursday,...
© 2011 AustrianTribune - Tribune Online Services. All times CET (GMT + 1.00).